Welcome to our dedicated page for Annovis Bio SEC filings (Ticker: ANVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Annovis Bio, Inc. filings document the regulatory record of a clinical-stage biotechnology company developing buntanetap for Alzheimer’s disease, Parkinson’s disease, and related neurodegenerative conditions. Recent Form 8-K reports cover operating results, Regulation FD materials, clinical and regulatory updates, material-event disclosure, exhibits, and changes in executive finance leadership.
Proxy materials describe annual-meeting proposals, director elections, stockholder voting procedures, board governance, and the company’s common stock structure. The filings also identify ANVS common stock as a New York Stock Exchange-listed security and provide capital-structure and governance disclosures relevant to the company’s development-stage business.
Annovis Bio, Inc. (ANVS) is asking stockholders at an October 14, 2026 special meeting to approve a major increase in its capital structure and to ratify a larger equity incentive pool. The company seeks to amend its certificate of incorporation to raise authorized common stock from 70,000,000 to 140,000,000 shares and authorized preferred stock from 2,000,000 to 10,000,000 shares, citing the need for flexibility to fund ongoing and future clinical trials, other research programs, and general corporate purposes, as well as to reserve shares for outstanding warrants and options.
Stockholders are also being asked to ratify a prior amendment to the 2019 Equity Incentive Plan to increase the plan’s share reserve to 5,500,000 and the maximum number of shares that may be awarded to any individual in a year from 400,000 to 600,000 shares, after a typographical error at the 2026 annual meeting understated the incremental increase. As of the September 4, 2026 record date, there were 42,679,059 common shares outstanding and approximately 21,210,026 additional shares issuable from options, plan reserves and warrants, leaving about 6.1 million authorized shares unissued. Directors and executive officers as a group beneficially owned about 15.92% of outstanding common stock and are expected to vote in favor of all proposals, including an adjournment authority to solicit additional proxies if needed.
Annovis Bio, Inc. (ANVS) is calling a virtual Special Meeting of stockholders in October 2026 to vote on several capital-structure and equity-compensation items. The board seeks approval of a Share Increase Amendment to its certificate of incorporation to raise authorized common stock from 70,000,000 to 140,000,000 shares and authorized preferred stock from 2,000,000 to 10,000,000 shares. As of the record date, 42,606,152 common shares were outstanding.
Stockholders are also asked to ratify an amendment to the 2019 Equity Incentive Plan, clarifying that the total share reserve is 5,500,000 shares (an incremental 2,500,000 above the previously approved 3,000,000) and increasing the maximum number of shares that may be awarded to any individual in one year from 400,000 to 600,000. As of December 31, 2025, 2,394,503 equity awards were outstanding under the plan, excluding contingent grants. A third proposal would allow adjournment of the meeting to solicit additional proxies if needed. The board unanimously recommends voting “FOR” all proposals.
Annovis Bio, Inc. is a late-stage clinical biopharmaceutical company developing its lead candidate buntanetap for Alzheimer’s and Parkinson’s disease. It reported a six-month net loss of $32.4 million, driven mainly by research and development expenses of $28.7 million as it advances a fully enrolled pivotal Phase 3 Alzheimer’s trial with 860 early AD patients and an open-label extension study in Parkinson’s disease.
Cash and cash equivalents were $18.7 million at June 30, 2026, while accumulated deficit reached $196.1 million. Management states that existing cash is expected to fund operations only into the fourth quarter of 2026 and concludes that substantial doubt exists about the company’s ability to continue as a going concern. To fund operations, Annovis raised equity during the period, increasing shares outstanding to 42.6 million and recognizing a warrant liability of $19.9 million from new liability-classified Canaccord warrants.
Annovis Bio, Inc. reported significantly higher operating losses for the quarter and six months ended June 30, 2026 while advancing its lead Alzheimer’s program. The company fully enrolled its pivotal Phase 3 trial in early Alzheimer’s disease with 850 patients and is planning an open-label extension to allow continued buntanetap treatment after trial completion. Topline data are targeted for early 2027, and preparations for a potential regulatory submission have begun.
For the quarter, operating expenses rose to $14.4 million from $6.3 million a year earlier, driven by research and development of $12.0 million versus $5.2 million. Net loss widened to $14.8 million from $6.2 million, and to $32.4 million for the first half of 2026 from $11.8 million. The balance sheet showed cash and cash equivalents of $18.7 million and a large increase in warrant liability to $19.9 million, resulting in negative stockholders’ equity of $(4.3) million as of June 30, 2026.
Highbridge Capital Management, LLC, as investment adviser to certain funds, reports beneficial ownership of 2,775,578 shares of Annovis Bio, Inc. common stock issuable upon exercise of warrants. This position represents 6.1% of the class, based on 42,541,868 shares of common stock outstanding after a referenced offering and assuming warrant exercise.
Highbridge has sole voting and dispositive power over these warrant shares. The Highbridge Funds, including Highbridge Tactical Credit Master Fund, L.P., have the right to receive dividends and sale proceeds from the shares. Highbridge states that filing this report does not constitute an admission of beneficial ownership for all purposes.
Empery Asset Management, LP and Ryan M. Lane report beneficial ownership of Annovis Bio, Inc. common stock. They report control over 2,401,476 shares of common stock, representing 5.64% of the class, based on 42,541,868 shares outstanding as of May 19, 2026.
The reporting persons hold no sole voting or dispositive power, but have shared voting and shared dispositive power over the 2,401,476 shares through funds managed by Empery Asset Management. Both Empery and Mr. Lane state that their beneficial ownership is only "deemed" and each disclaims beneficial ownership of shares held by the other reporting person.
Annovis Bio, Inc. reported that it has fully enrolled its pivotal Phase 3 trial (NCT06709014) of oral buntanetap in patients with early Alzheimer’s disease. The study enrolled 850 patients with pTau217-confirmed Alzheimer’s pathology across 83 clinical sites in the United States, exceeding the company’s original enrollment projections.
The randomized, placebo-controlled, double-blind dual trial evaluates daily 30mg buntanetap in early Alzheimer’s patients with MMSE scores of 20–28. Primary endpoints focus on changes in cognition using ADAS-Cog13 and function using ADCS-iADL. The design includes two pre-specified analyses: a 6‑month symptomatic readout and an 18‑month disease-modifying readout, each intended to support a separate NDA submission.
The last patient is expected to complete the 6‑month treatment period in January 2027, with top-line symptomatic data targeted for Q1 2027 and disease-modifying data in Q1 2028. Annovis has begun preparations for New Drug Application submissions to the FDA following each respective data readout.
Annovis Bio, Inc. reported the results of its 2026 Annual Meeting of Stockholders, where all five proposals received the required stockholder approval. Stockholders elected five directors for one-year terms and ratified the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm.
Investors also approved an amendment to the 2019 Equity Incentive Plan, increasing the total shares available from 4,000,000 to 5,500,000 and raising the maximum annual award from 400,000 to 600,000 shares. Stockholders gave advisory approval to executive compensation and recommended holding future say‑on‑pay votes every two years, a frequency the board has adopted until the next required vote on this topic.
Annovis Bio director Michael B. Hoffman reported new open-market purchases of company stock. On May 20, 2026, he bought a total of 76,344 shares of Annovis Bio common stock in three open-market transactions at prices between $1.75 and $1.8999 per share.
Following these transactions, Hoffman directly holds 3,364,883 shares of common stock. A separate entry also reports 223,357 shares held indirectly through The 2024 Hoffman Family Trust, over which he has voting and investment power according to the filing footnote.
Annovis Bio, Inc. entered an underwriting agreement for an underwritten public offering of 7,895,000 shares of common stock and accompanying warrants, targeting gross proceeds of about $15 million before expenses. Each share is sold together with nine-tenths of a warrant at a combined price of $1.90.
The warrants cover up to 7,105,500 shares, are immediately exercisable at $2.25 per share, and expire six years after issuance. Annovis plans to use the net proceeds primarily to continue clinical development of its lead drug candidate buntanetap for Alzheimer’s and Parkinson’s disease, and for working capital and general corporate purposes.